1297-P: Hypergliptinemia —A Compensatory Phenomenon Observed in Asian Population with Newly Diagnosed Type 2 Diabetes Mellitus

Introduction 1 year vs ≥ 1 year of disease duration to elicit if there are any subtle differences in their respective GLP-1 responses. Results: Total GLP-1 levels at fasting (fGLP-1) and 30 min (GLP-130min) were significantly higher in T2DM than NGT (fGLP-1 27.18±11.56 pmol/L vs. 16.24 ±7.79 pmol/L, p0.005; GLP-130min 50.22±18.03 pmol/L vs. 31.44 ±22.59 pmol/L, p0.001; respectively). The GLP-1 levels were positively correlated with HOMA-IR and TyG index but negatively correlated with HOMA-IS. T2DM subjects with disease duration 1 year had higher GLP-1 response than those with disease duration ≥1 year (GLP-130min 55.33±18.09 pmol/L vs. 46.02±17.12 pmol/L, p0.05). Conclusion: The augmented GLP-1 levels in T2DM represents an adaptive compensatory response to increasing insulin resistance, a phenomenon we aptly refer to as “hypergliptinemia”. However, this phenomenon is transient as the incretin response started to diminish after one year of diagnosis in keeping with the progressive nature of T2DM. Disclosure S. Chong: None. N. Sukor: None. S.A. Robert: None. K. Ng: None. N.A. Kamaruddin: Speaker's Bureau; Boehringer-Ingelheim, Novo Nordisk, AstraZeneca. Funding Universiti Kebangsaan Malaysia (GUP-2017-066); Malaysian Endocrine and Metabolic Society (L12-MEMS6)